phorbolol myristate acetate has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Romanchikova, N; Trapencieris, P; Turks, M; Zemītis, J | 1 |
| Amin, MA; Arasu, E; Balogh, B; Campbell, PL; Haines, GK; Kahaleh, B; Khanna, D; Koch, AE; Lozier, A; Ohara, RA; Rabquer, BJ; Renauer, PA; Schiopu, E; Stinson, WA; Tsou, PS; Zakhem, G | 1 |
2 other study(ies) available for phorbolol myristate acetate and Angiogenesis, Pathologic
| Article | Year |
|---|---|
A novel matrix metalloproteinase-2 inhibitor triazolylmethyl aziridine reduces melanoma cell invasion, angiogenesis and targets ERK1/2 phosphorylation.
Topics: Animals; Aziridines; Cell Line, Tumor; Cell Movement; Collagen; Diffusion Chambers, Culture; Drug Combinations; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Laminin; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Melanoma, Experimental; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Phosphorylation; Proteoglycans; Signal Transduction; Tetradecanoylphorbol Acetate; Triazoles; Vascular Endothelial Growth Factor A | 2014 |
Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines.
Topics: Angiogenesis Inducing Agents; Case-Control Studies; Cells, Cultured; Chemokines; Chemotaxis; Endothelial Cells; Endothelium, Vascular; Female; Humans; Inhibitor of Differentiation Protein 1; Male; Middle Aged; Neovascularization, Pathologic; Receptors, Interleukin-8B; Scleroderma, Systemic; Signal Transduction; Skin; Tetradecanoylphorbol Acetate | 2016 |